Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy
Abiraterone blocks androgen synthesis and prolongs survival in castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis1,2. Abiraterone is metabolized in patients to D4A, which has even greater anti-tumor activity and structural similarities to endogenous st...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111629/ |